# Unique Treatment of Oncology Pain in Advanced Cancer

> **NCT06533657** · PHASE2 · COMPLETED · sponsor: **ZYUS Life Sciences Inc.** · enrollment: 11 (actual)

## Conditions studied

- Cancer Pain

## Interventions

- **DRUG:** Trichomylin® capsule (5 mg delta-9-tetrahydrocannabinol: 5 mg cannabidiol: 5 mg cannabichromene)

## Key facts

- **NCT ID:** NCT06533657
- **Lead sponsor:** ZYUS Life Sciences Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-06-12
- **Primary completion:** 2026-04-15
- **Final completion:** 2026-04-15
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2026-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06533657

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06533657, "Unique Treatment of Oncology Pain in Advanced Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06533657. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*